<rss version="2.0">
<channel>
<title>IBTimes.com RSS Feed - health</title>
<description>International Business News - health</description>
<link>http://www.ibtimes.com</link>
<copyright>All articles are copyrighted by IBTimes.com</copyright>

<image>
	<title>The International Business Times - Business News, Updated daily</title> 
	<width>400</width> 
	<height>100</height> 
	<link>http://www.ibtimes.com/</link> 
	<url>http://www.ibtimes.com/images/top_logo_ibt2_3.gif</url> 
</image>


  <item>
  <title>Canada scraps development of medical isotope reactors</title>
  <description>Canadian energy officials Friday scrapped development of a nuclear reactor project to produce radioactive isotopes for the diagnoses of cancer and other illnesses, citing costs of the program.</description>
    <link>http://www.ibtimes.com/articles/20080516/canada-scraps-development-of-medical-isotope-reactors.htm</link> 
  <pubDate>Fri, 16 May 2008 18:18:39 EDT</pubDate>
  </item>


  <item>
  <title>Drug maker settles federal probe for $24.6M</title>
  <description>A unit of Biovail has agreed to pay nearly $25 million to settle federal criminal charges that it illegally paid doctors so that they would prescribe a blood pressure drug.</description>
    <link>http://www.ibtimes.com/articles/20080516/drug-maker-settles-federal-probe-for-24-6m.htm</link> 
  <pubDate>Fri, 16 May 2008 17:27:24 EDT</pubDate>
  </item>


  <item>
  <title>Shareholders sue to block $17 million CryoCor deal</title>
  <description>A group of shareholders has sued CryoCor Inc. and Boston Scientific Inc., seeking to block the medical device makers' $17.2 million deal. The shareholders filed a complaint in California Superior Court, San Diego County, alleging the two companies breached their responsibilities to shareholders in making a deal for Boston Scientific to buy CryoCor for $17.2 million in cash.</description>
    <link>http://www.ibtimes.com/articles/20080516/shareholders-sue-to-block-17-million-cryocor-deal.htm</link> 
  <pubDate>Fri, 16 May 2008 16:30:29 EDT</pubDate>
  </item>


  <item>
  <title>Closing glance: health care equipment and supplies</title>
  <description>Health care equipment and supply stocks close mixed Friday. The broader market dipped slightly as oil prices hit a new record of more than $127 a barrel.</description>
    <link>http://www.ibtimes.com/articles/20080516/closing-glance-health-care-equipment-and-supplies.htm</link> 
  <pubDate>Fri, 16 May 2008 16:09:58 EDT</pubDate>
  </item>


  <item>
  <title>Sector Wrap: Celgene, Genentech in ASCO spotlight</title>
  <description>Analysts said Celgene Corp. and Genentech Inc. are their top picks heading into the 44th annual American Society of Clinical Oncology meeting, or ASCO, taking place May 30 to June 3 in Chicago.</description>
    <link>http://www.ibtimes.com/articles/20080516/sector-wrap-celgene-genentech-in-asco-spotlight.htm</link> 
  <pubDate>Fri, 16 May 2008 16:04:04 EDT</pubDate>
  </item>


  <item>
  <title>A Second Look: Prestige Brands rally continues</title>
  <description>Prestige Brands Holdings Inc. shares continued to rally Friday, a day after the distributor of drugs and personal care products said higher prices helped drive double-digit growth in earnings.</description>
    <link>http://www.ibtimes.com/articles/20080516/a-second-look-prestige-brands-rally-continues.htm</link> 
  <pubDate>Fri, 16 May 2008 17:12:09 EDT</pubDate>
  </item>


  <item>
  <title>Specialty drugs will benefit PBMs: Goldman analyst</title>
  <description>Pharmacy benefit managers that have a strong footprint in specialty pharmaceuticals stand to benefit as drug spending in the area is expected to grow three times as much as other pharmaceuticals, according to a Goldman Sachs analyst.</description>
    <link>http://www.ibtimes.com/articles/20080516/specialty-drugs-will-benefit-pbms-goldman-analyst.htm</link> 
  <pubDate>Fri, 16 May 2008 15:14:07 EDT</pubDate>
  </item>


  <item>
  <title>Dusa Pharmaceuticals files shelf registration</title>
  <description>Dusa Pharmaceuticals Inc., which makes dermatology products, said Friday it has filed a shelf registration statement with the Securities and Exchange Commission to offer up to $75 million of securities.</description>
    <link>http://www.ibtimes.com/articles/20080516/dusa-pharmaceuticals-files-shelf-registration.htm</link> 
  <pubDate>Fri, 16 May 2008 14:36:22 EDT</pubDate>
  </item>


  <item>
  <title>Movers roundup: Melco, Pharmasset</title>
  <description>Among the stock activity stories for Friday, May 16, from AP Financial News: NEW YORK (AP) _ Shares of Melco PBL Entertainment Inc. fell Friday as investors largely discounted the benefits of the company's agreement with A-Max Holdings, according to an analyst.</description>
    <link>http://www.ibtimes.com/articles/20080516/movers-roundup-melco-pharmasset.htm</link> 
  <pubDate>Fri, 16 May 2008 14:32:46 EDT</pubDate>
  </item>


  <item>
  <title>Biovail settles Justice Department probe for $24.6M</title>
  <description>Specialty pharmaceutical comnpany Biovail Corp. Friday said it reached a settlement with the Justice Department in regard to a criminal investigation regarding the launch of the blood pressure medication Cardizem LA.</description>
    <link>http://www.ibtimes.com/articles/20080516/biovail-settles-justice-department-probe-for-24-6m.htm</link> 
  <pubDate>Fri, 16 May 2008 14:31:51 EDT</pubDate>
  </item>


  <item>
  <title>Covidien CFO exercises options for 20,905 shares</title>
  <description>The chief financial officer of medical device maker and diversified health care company Covidien Ltd. exercised options for 20,905 shares of common stock, according to a Securities and Exchange Commission filing Thursday.</description>
    <link>http://www.ibtimes.com/articles/20080516/covidien-cfo-exercises-options-for-20-905-shares.htm</link> 
  <pubDate>Fri, 16 May 2008 13:45:39 EDT</pubDate>
  </item>


  <item>
  <title>Covidien CEO Meelia exercises options for shares</title>
  <description>The president and chief executive of medical device maker and diversified health care company Covidien Ltd. exercised options for 306,197 shares of common stock, according to a Securities and Exchange Commission filing Thursday.</description>
    <link>http://www.ibtimes.com/articles/20080516/covidien-ceo-meelia-exercises-options-for-shares.htm</link> 
  <pubDate>Fri, 16 May 2008 13:44:50 EDT</pubDate>
  </item>


  <item>
  <title>Pharmasset shares up; analysts upbeat on hepatitis candidate</title>
  <description>Shares of clinical-stage pharmaceutical company Pharmasset Inc. rose Friday after analysts expressed optimism about the company's hepatitis Cdrug candidate in partnership with Roche AG.</description>
    <link>http://www.ibtimes.com/articles/20080516/pharmasset-shares-up-analysts-upbeat-on-hepatitis-candidate.htm</link> 
  <pubDate>Fri, 16 May 2008 17:15:56 EDT</pubDate>
  </item>


  <item>
  <title>Gilead Sciences CEO exercises options</title>
  <description>The chairman and chief executive of biopharmaceutical company Gilead Sciences Inc. exercised options for 70,000 shares of common stock, according to a Securities and Exchange Commission filing Thursday.</description>
    <link>http://www.ibtimes.com/articles/20080516/gilead-sciences-ceo-exercises-options.htm</link> 
  <pubDate>Fri, 16 May 2008 13:23:27 EDT</pubDate>
  </item>


  <item>
  <title>FDA stresses birth defect risks with Roche drug</title>
  <description>Health regulators warned again Friday that Roche and Novartis drugs prescribed to organ transplant patients can cause miscarriages and birth defects when used by pregnant women.</description>
    <link>http://www.ibtimes.com/articles/20080516/fda-stresses-birth-defect-risks-with-roche-drug.htm</link> 
  <pubDate>Fri, 16 May 2008 16:56:32 EDT</pubDate>
  </item>


  <item>
  <title>Cephalon spent $512,000 on lobbying in first quarter</title>
  <description>Biotech drugmaker Cephalon spent more than $512,000 lobbying the federal government in the first quarter, according to a government disclosure form. Cephalon lobbied in favor of more funding for the Food and Drug Administration, which reviews the safety of all new medicines in the U.S.</description>
    <link>http://www.ibtimes.com/articles/20080516/cephalon-spent-512-000-on-lobbying-in-first-quarter.htm</link> 
  <pubDate>Fri, 16 May 2008 12:41:55 EDT</pubDate>
  </item>


  <item>
  <title>Alkermes rises as analyst names it a 'Top Pick'</title>
  <description>Alkermes Inc. shares rose Friday after an analyst predicted stronger sales of its schizophrenia drug Risperdal Consta and good clinical data for a diabetes drug candidate.</description>
    <link>http://www.ibtimes.com/articles/20080516/alkermes-rises-as-analyst-names-it-a-top-pick.htm</link> 
  <pubDate>Fri, 16 May 2008 17:19:37 EDT</pubDate>
  </item>


  <item>
  <title>Schering-Plough CEO says rebuilding plan on track</title>
  <description>Schering-Plough Corp.'s chief executive told shareholders Friday the company remains on track five years into his rebuilding program, with a wider range of products and more drugs in late-stage development.</description>
    <link>http://www.ibtimes.com/articles/20080516/schering-plough-ceo-says-rebuilding-plan-on-track.htm</link> 
  <pubDate>Fri, 16 May 2008 17:01:12 EDT</pubDate>
  </item>


  <item>
  <title>Mentor shares rise despite fiscal year 2009 estimates</title>
  <description>Shares of cosmetic surgery products maker Mentor Corp. rose Friday, even after the company gave fiscal year 2009 profit estimates that fell short of Wall Street expectations.</description>
    <link>http://www.ibtimes.com/articles/20080516/mentor-shares-down-on-fiscal-year-2009-estimates.htm</link> 
  <pubDate>Fri, 16 May 2008 17:24:15 EDT</pubDate>
  </item>


  <item>
  <title>Eli Lilly says Alimta helps lung cancer patients</title>
  <description>Eli Lilly &amp; Co. said giving advanced lung cancer patients its Alimta drug after chemotherapy increased patients' survival without tumor recurrence or progression.</description>
    <link>http://www.ibtimes.com/articles/20080516/eli-lilly-says-alimta-helps-lung-cancer-patients.htm</link> 
  <pubDate>Fri, 16 May 2008 12:50:32 EDT</pubDate>
  </item>


</channel>
</rss>